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Progress in the treatment of bipolar disorder
Bipolar affective disorder has long been recognized as being one of the most
significant causes of increased mortality and morbidity due to mental ill health. Bipolar
disorder is an evolution of the older concept of manic-depressive illness, which itself
was differentiated from dementia praecox/schizophrenia by Kraepelin over 100 years
ago. Bipolar disorder was further differentiated from severe unipolar disorder
following research in Europe by Angst and Perris and in the US by Winokur in the
1960s. However, unipolar and bipolar disorders are undeniably closely related, with
unipolar disorder being the commonest illness in offspring of bipolar parents. Bipolar
disorder has itself been subdivided into bipolar I disorder (with a history of mania)
and bipolar II disorder (with a history of hypomania).
The recent “Burden of Disease” studies published in the last 10 years which have
quantified the amount of years of healthy life lost to all illness show that bipolar
affective disorder is one of the leading causes of increased disease burden within
mental health, being roughly equal to schizophrenia (Murray and Lopez 1996).
Despite the clinical importance of bipolar disorders, they have received relatively
less attention both in terms of health care funding and research than other major
psychiatric disorders such as schizophrenia and major depression, which of course
are themselves under-funded. This has changed somewhat recently due to the advent
of novel treatments for the various phases of bipolar disorder. Lithium in its various
forms has been used for over 50 years as a recognized medication for the treatment
of both mania and depression, and the maintenance of wellness in bipolar disorder.
However, after the introduction of lithium there was a long gap before the introduction
of other novel treatments such as the anticonvulsants and atypical antipsychotics.
Recently, there has been a welcome increase in the literature on the treatment of
bipolar disorder. It is therefore very timely that this issue of Neuropsychiatric Disease
and Treatment contains three review articles which bring us up to date with various
developments in the treatment of bipolar disorders.
In the first review, Professor Charles Bowden and Dr Vivek Singh from the
Department of Psychiatry, San Antonio, Texas, review treatment options and patient
satisfaction in bipolar disorders. Charles Bowden is the principal author of many
seminal works on the treatment of bipolar disorder and is particularly associated
with the introduction of novel treatments, having authored landmark studies on the
efficacy of drugs such as divalproex (with lithium as a comparator) and atypical
antipsychotics. Professor Bowden and Dr Singh focus their research on functional
recovery, which is of course the goal of treatment but has long been overlooked in
the assessment of effective pharmacological treatments. They review the comparative
function of individuals with both bipolar disorder and major depression and the
relationship of syndromal to functional improvement, and cogently discuss efficacy
versus effectiveness. They then review the various drugs from lithium through the
anticonvulsants and antipsychotics with regard to their potential to alter function in
patients.
The next two reviews concern atypical antipsychotics. Dr Emanuela Mundo and
colleagues from Milan, Italy review the use of atypical antipsychotics “beyond
psychoses”, in particular the efficacy of quetiapine in bipolar disorder. The authors
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disorder either as adjunctive treatments or as monotherapy.
They particularly focus on quetiapine, which has previously
been used as a treatment in schizophrenia and is beginning
to be used widely as both an antimanic and antidepressive
treatment. They conclude that quetiapine is an effective
agent for short- and long-term treatment of bipolar disorder,
although the mechanisms of action for the various antimanic
and antidepressive actions of quetiapine remain unclear.
Some preliminary data suggest involvement of glutamate
pathways, but the authors advise that further studies are
required to clarify these issues.
The third review is by Dr Martha Sajatovic and
colleagues from Case Western University in Ohio. Dr
Sajatovic and colleagues note that atypical antipsychotic
medications have assumed growing importance for the
treatment of bipolar disorder, and that current practice
guidelines in various parts of the world recommend atypical
antipsychotic medication as monotherapy or as a component
of polytherapy in the treatment of bipolar disorder. They
then review the evidence base supporting the use of
risperidone in bipolar disorder. Most importantly, they
describe dosing and administration in special populations
such as geriatric, child, or adolescent patients.
These reviews are greatly to be welcomed. They
consolidate and summarize much of the evidence base
acquired from the last 5–10 years of research. It must be
noted, however, that the only drug that has been introduced
for the treatment of bipolar disorder a priori is lithium.
Anticonvulsants, antipsychotics, and, indeed,
antidepressants have been initially indicated and most
extensively investigated in other psychiatric diseases. With
the renewed interest in the treatment of bipolar disorder
documented in these reviews, it is to be hoped that drug
development will now focus on pharmacological treatments
specific for bipolar disorder.
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